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Abstract
Purpose: Nurse practitioners, physician assistants, and pharmacists are advanced practice providers who are highly
trained and qualified healthcare professionals that can help support traditional demands on oncologists’ increased time in
direct patient care. The purpose of this study was to detail and assess the creation of a privileging process for this group
of medical professionals within an academic medical center. Obtaining the designation of limited oncology practice
provider (LOPP) gives the right to modify chemotherapy orders and to order supportive care medications.
Methods: An interdisciplinary team developed a comprehensive training process inclusive of required educational
domains, knowledge goals, and educational activities to become an LOPP. In 2018, five years after the implementation
of the privileging process, a survey was distributed to assess perceptions of the training process and integration of LOPPs
within oncology practice.
Results: Most oncologists noted that working with LOPPs is beneficial to oncology practice (94%) and that they make
modifying chemotherapy orders more efficient (87%). Greater than 82% of LOPPs also reported that their privileges
streamline the chemotherapy process and make them feel valuable.
Conclusion: The creation of the LOPP designation is an effective way to integrate nurse practitioners, physician
assistants, and pharmacists within oncology practice. The inclusion of a focused privileging process ensures the safety
of cancer care provided and has created a streamlined process for chemotherapy modifications and supportive care.
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Background
Research over the past few years has identified the like-
lihood of a significant shortage of oncology profes-
sionals beginning as soon as 2020.1 This is mostly due
to the growing number of current oncology profes-
sionals in the workforce that are nearing retirement
and the growing patient population that is anticipated
to have cancer.1,2 The anticipated shortage has the
potential to strain the quality of cancer care provided
unless work demands and productivity can be opti-
mized. With these concerns imminently on the horizon,
the opportunity for advanced practice providers (APPs)
to have expanded roles within oncology care models
has become a more prominent discussion.3 The inclu-
sion of APPs in daily workflows could help alleviate
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some of the traditional demands on oncologists and
allow for more direct patient care time, resulting in
higher quality patient care and greater job satisfaction
for practitioners.4–6
Historically, the APP designation has referred to
either nurse practitioners (NP) or physician assistants
(PA).2 In more recent years, there has also been litera-
ture published to support the role of pharmacists to be
recognized as APPs due to their expert knowledge of
medications, including chemotherapy and the asso-
ciated adverse effects.6–9 Overall, APPs are highly
trained and qualified medical professionals that play a
vital role in providing clinical care to patients with
cancer.4,7,10 The American Society of Clinical
Oncology’s (ASCO) annual, national practice survey
demonstrated that APPs are involved in providing
care within various capacities to patients in the major-
ity of oncology clinical practices across the nation.
Their reported responsibilities included: ordering and
administering chemotherapy, managing adjuvant thera-
pies and providing primary care to cancer patients and
survivors.2 Individual institutions and healthcare sys-
tems have the ability to determine how best to integrate
APPs into their oncology practice.
Hospitals may choose to offer credentialing and pri-
vileging opportunities for APPs to involve them in
more complex roles in oncology patient care.11
Credentialing, introduced in the 1989 accreditation
standards by The Joint Commission (TJC), is the pro-
cess utilized by hospitals to validate employees’ licen-
sure, experience, and preparation for specialty practice,
usually prior to employment.3,12 Privileging is an add-
itional process conducted by organizations to authorize
and allow for additional job function privileges within
an individual’s specified scope of practice.12 TJC details
the components of a privileging process to include the
creation of a procedures list, application process, evalu-
ation process, specifying delineated privileges, notifying
the relevant personnel of privileges, and monitoring of
privileges and quality of care issues.3,11,12
One such complex role in oncology patient care,
where privileging could be considered, is the process
of ordering and modifying chemotherapy regimens.
Managing chemotherapy orders presents a high level
of complexity due to the risk for medication errors,
the narrow therapeutic range of agents, the need for
frequent dose adjustments, and the increasing number
of regimens available. Each step from entering an order
to the final administration to the patient represents a
potential significant source of error.13–17
In 2013, our institution, an 803-bed academic
medical center with a National Cancer Institute
(NCI)-designated cancer hospital, initiated a privileging
process for APPs to earn the additional designation
of limited oncology prescribing provider (LOPP).
LOPPs are allowed to modify and discontinue chemo-
therapy orders and prescribe supportive medications.
Adjunctive medications added to chemotherapy
orders must be signed by a physician. The need for
the LOPP designation originated in the outpatient infu-
sion clinic setting as the clinic was physically located on
different floors than physician workspaces.
Consequently, there was a consistently high volume of
phone calls and pages to physicians. To alleviate the
demand on physicians and to help improve infusion
clinic efficiency, safety, and the patient care experience,
it was determined that PA, NP, and oncology clinical
pharmacy specialists (OCPS) may serve as LOPPs after
undergoing a tailored training program and being
granted the institutional designation by the Pharmacy
and Therapeutics Committee. The implementation of
the LOPP privileging process was so successful in the
outpatient infusion clinic that it was further imple-
mented in inpatient practices beginning in 2015 and in
other outpatient oncology clinics in 2016.
Established in 1952, the University of North Carolina
Medical Center (UNCMC) is home to a Cancer
Hospital, which is the flagship site for our health sys-
tem’s Cancer Care. It is also the clinical home of the only
public NCI-designated comprehensive cancer center in
our state. Approximately 100,000 patients from all
over the state visit the Cancer Hospital annually. The
purpose of this article is to detail our institution’s pro-
cess for developing training competencies and imple-
menting a privileging process for LOPPs to grant
additional chemotherapy prescribing privileges.
Methods
In order to successfully develop practitioners and
ensure patient safety, an interdisciplinary team consist-
ing of physicians and pharmacists collaborated to
develop a robust training process. However, PA and
NP were included in the program. The team developed
the required process, educational domains, knowledge
goals, and the educational activities needed to support
the achievement of the learning objectives relevant to
practice as an LOPP.
The privileging process for PAs and NPs included
training with an OCPS, completion of readings pertain-
ing to chemotherapy orders, a simulated clinical skills
module for chemotherapy orders, and a written exam-
ination. In order for OCPSs to become LOPPs, they
were required to be a Board Certified Oncology
Pharmacist (BCOP) prior to taking the written exam-
ination. The BCOP designation demonstrates a
pharmacist’s advanced oncology knowledge and experi-
ence. Additionally, BCOP represents a high level of
professional competence to recommend, implement,
monitor, and modify chemotherapy orders.18
The overall training process developed, as delineated
in a stepwise process in Figure 1, was initiated by the
Division Chief of Hematology/Oncology employing the
provider or their designee and had to be approved by
the Pharmacy and Therapeutics Committee.
Completion of these items was coordinated by the
Division Chief’s designee, the Assistant Director, or
Clinical Manager of the Hematology/Oncology
Pharmacy Service Line. Successful completion of each
step in the process was defined as receiving an 80% pass
rate for each of the steps. Upon successful completion
of the requirements, security access in the electronic
medical record (EMR) was adjusted for individuals to
reflect LOPP privileges.
LOPP educational training
The following educational domains were identified as
necessary for LOPP privileging: medication manage-
ment, safe handling of hazardous substances, determin-
ing ‘‘ok to treat’’, and modifying chemotherapy orders.
It was determined that medication management would
be defined by the following job functions: prescribing,
dispensing, monitoring and administration of chemo-
therapy, biotherapy, and immunotherapy. For each
educational domain, LOPP candidates were provided
with a list of required readings that were identified to
provide an in-depth background. Additionally, each
educational domain was paired with a practical appli-
cation of knowledge activity. All of the knowledge
goals that were agreed upon and that were associated
with mastering each educational domain can be seen in
Table 1.
Chemotherapy order review
As part of the practical application activities to be com-
pleted, LOPP candidates had to practice reviewing
chemotherapy written orders for accuracy. Objectives
created for assessing the accuracy of each order are
listed below:
1. Calculate body surface areas and carboplatin doses
2. Calculate dose modifications (reduction/increase)
based on percent desired by attending physician
3. Review chemotherapy orders for accuracy and indi-
vidualization for a given patient
4. Understand intrathecal chemotherapy pharmacol-
ogy and associated primary literature
5. Design preventative antiemetic regimens appropriate
for a given chemotherapy regimen
6. Apply institution-specific policy for ‘‘Medication
Management: Prescribing, Dispensing, Monitoring,
and Administration of Chemotherapy, Biotherapy,
and Immunotherapy’’ to practice.
EMR simulation training
After passing the educational portion of the LOPP pri-
vileging process, LOPP candidates were given access to
a simulated EMR environment to learn how to navi-
gate orders appropriately. The simulation consisted of
three patient scenarios each with associated chemother-
apy orders. The chemotherapy orders included errors of
omission, dose, route, and dose adjustments for organ
function. LOPP candidates were instructed to identify
the errors and modify the orders as clinically appropri-
ate with a passing score defined as an 80% or higher on
the competency rubric.
Written examination
A 33-question multiple choice exam was developed to
assess all of the knowledge goals. The exam was a mix-
ture of knowledge-based questions and case-based
questions. All questions included within the exam
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Figure 1. LOPP privileging process.
LOPP: limited oncology practice provider; PA: physician assistants; NP: nurse practitioners.
Table 1. Knowledge-based learning checklist.
Knowledge-based learning
3 These knowledge-based components are matched with educational activities designed to support achievement of learning object-
ives relevant to practice as an LOPP. Achievement of these knowledge-based learning objectives will support achievement of skill-
based learning objectives. Trainees should reflect on achievement of each learning objective using the objectives as a measure to gauge
readiness to advance through the credentialing process. Please see your trainer to arrange for two didactic session dates/times.
Goal: To provide advanced practice practitioners (APP) with oncology background that supports achievement of privileging to provide
care as an LOPP.
Goal/objective Learning activities to support objectives
Domain 1: Medication management: Prescribing, dispensing, monitoring
and administration of chemotherapy, biotherapy and immunotherapy
(Chemotherapy policy admin 0188)
Trainer:
Knowledge goal 1.1: Definitions relevant to Beacon
Define the following: EPIC Beacon treatment plan, Willow, Springboard
report
Introduction to oncology at our institution (1 h)
Reading: Chemotherapy policy
Knowledge Goal 1.2: LOPP privileges and security access
Define authorized prescriber
Identify when a LOPP has privileges to modify a chemotherapy order
Identify type of chemotherapy modification that an LOPP is privileged
to enter
Describe documentation requirements for chemotherapy modification in
the acute and ambulatory care environment
Explain differences between acute care chemotherapy orders (e.g. ‘‘giant
super day’’) and ambulatory care chemotherapy orders
Explain documentation requirements for intrathecal chemotherapy
orders to identify the location of the procedure in the acute care
environment
Introduction to oncology at our institution (1 h)
Reading: Chemotherapy policy
Knowledge Goal 1.3: Institution’s chemotherapy use process
Describe safety measures included in the following points of the
chemotherapy use process: (a) chemotherapy order/prescription,
(b) drug preparation and dispensing, (c) patient consent and educa-
tion, (d) chemotherapy administration, (e) monitoring and assessment
Introduction to oncology at our institution (1 h)
Readings:
(1) Chemotherapy policy
(2) 2013 ASCO guidelines on chemotherapy
administration
Domain 2: Safe handling of hazardous substances Trainer:
Knowledge Goal 2.2: Personal protective equipment (PPE) and mitigating
exposure risk
Identify scenarios when PPE for handling antineoplastic agents is
necessary
Describe the components of PPE needed when handling antineoplastic
agents
Identify individuals that should not handle antineoplastic agents (e.g.
women and men of childbearing age trying to conceive, pregnant or
nursing mothers)
Explain four ways exposure to hazardous substances can occur (e.g.
(1) ingestion, (2) inhalation, (3) dermal absorption, and (4) accidental
injection)
Describe methods to mitigate exposure risk to hazardous substances
Introduction to Oncology at our institution (1 h)
Reading:
(1) ASHP guidelines on handling hazardous drugs
(2) Appendix A to ‘‘Handling and Disposal of
Hazardous Drugs’’ policy
(3) Policy requirements on personal protective
equipment
Knowledge Goal 2.3: Preventing errors with antineoplastic agents
Define independent double check (in the context of both the chemo-
therapy order and the product at the point of administration)
Explain the ‘‘time out’’ procedure
Introduction to oncology at our institution (1 h)
Readings:
(1) Chemotherapy policy
(2) ASHP guidelines on preventing medication errors
with chemotherapy and biotherapy
(3) ‘‘Universal Protocol for Preventing Wrong
Patient, Wrong Procedure, Wrong Site Surgery’’
policy




Domain 3: Determining ‘‘ok to treat’’ Trainer:
Knowledge Goal 3.1: Supportive care
Classify chemotherapy regimens/agents according to emetogenic
potential
Define acute nausea/vomiting, anticipatory nausea/vomiting, delayed
nausea/vomiting
Describe classes of medications used to prevent nausea/vomiting
Identify when pairing ifosfamide or cyclophosphamide with the chemo-
protectant mesna is necessary
Describe supportive care components of high-dose methotrexate
(>500 mg/m2) and high-dose cytarabine (>1 g/m2)
Describe supportive care components of irinotecan-induced diarrhea
Recall the standard operating procedures for antimicrobial prophylaxis
use in hematologic malignancy patients
Describe criteria that should be met for use of growth factor support
with filgrastim, tbo-filgrastim or pegfilgrastim
Identify cases in which growth factor support is necessary
Explain monitoring parameters for intrathecally administered chemo-
therapy
Describe hydration used with cisplatin chemotherapy
Practical application of examining chemotherapy
orders (3 h)
Readings:
(1) Procedure on antimicrobial prophylaxis
(2) ASCO antiemetic guidelines
(3) Institution-specific antiemetic guidelines
(4) Chemotherapy-induced diarrhea guidelines
(5) Prevention and management of high-dose
methotrexate toxicity
(6) Nursing policy on assessing adult cerebellar
toxicity
(7) ASCO growth factor support guidelines
(8) Fellow presentation on intrathecal chemotherapy
(9) Cisplatin renal toxicity and mannitol
Knowledge Goal 3.2: Chemotherapy and organ function
Describe the dose-limiting toxicity of bleomycin (e.g. bleomycin-induced
lung toxicity)
Explain what patient examination measures are taken prior to adminis-
tration of bleomycin and methotrexate
Identify agents that require evaluation of cardiac function before
chemotherapy (e.g. doxorubicin, daunorubicin, idarubicin, and
mitoxantrone)
Explain how cardiac function is evaluated prior to chemotherapy
Explain how to determine lifetime cumulative dose limits for relevant
chemotherapy agents (e.g. doxorubicin, daunorubicin, idarubicin,
mitoxantrone and bleomycin)
Identify laboratory tests commonly used in cancer treatment to assess
organ function prior to chemotherapy (e.g. CBC with differential and
chemistry panels)
Determine laboratory values applicable to different anticancer drugs or
be able to locate resources which contain this information
Describe dose-limiting toxicities for major classes of chemotherapy (e.g.
alkylating agents, topoisomerase inhibitors, anthracyclines, epipodo-
phyllotoxins, antimicrotubule agents, taxanes, antimetabolites, mono-
clonal antibodies, tyrosine kinase inhibitors)
Practical application of examining chemotherapy
orders (3 h)
Readings:
(1) Basic review: Laboratory monitoring in oncology
Knowledge Goal 3.3: Chemotherapy dosing
Outline a standardized method used to analyze a chemotherapy order
(e.g. PRONTO)
Recall the Mosteller and/or Dubois equation for calculating a body
surface area
Recall the Calvert equation for calculating a carboplatin dose
Practical application of examining chemotherapy
orders (3 h)
Reading: Chemotherapy dosing part I: scientific basis
for current practice and use of body surface area
Domain 4: Modifying chemotherapy orders Trainer:
Knowledge Goal 4.1: Chemotherapy dosing adjustments
Identify commonly used chemotherapy agents that require dose adjust-
ment for renal and/or hepatic dysfunction
Describe issues to consider when determining chemotherapy dosing or
agent selection in patients with renal and/or hepatic dysfunction
Practical application of examining chemotherapy
orders (3 h)
Reading: Oncology drugs in organ dysfunction
(continued)
throughout the training process. LOPP candidates
worked independently on the exam but were allowed
to reference resources in order to mimic actual daily
practice within the institution.
Survey
In 2018, five years after the development of LOPP, a
survey was developed to assess perceptions associated
with the LOPP training program and the overall LOPP
designation. It was distributed to physicians and
LOPPs (NPs, PAs, and pharmacists) for completion.
The survey questions were targeted at assessing the
training process, and the impact that serving as a
LOPP has had on medical services and clinics, and
ultimately the patients. The questions from the survey
are documented in Table 2.
Results
The survey had a 47% response rate with 35 out of
75 potential responders completing it. The breakdown
of responders to the survey is illustrated in Table 3.
Overall, there was a slightly greater physician response
rate. A similar response rate was seen between the
PA/NP LOPP and the pharmacist LOPP group. The
physician group who completed the survey noted
that 86% (13 responders) interact with a LOPP very
often and 13% (2 responders) interact often. When it
came to modifying chemotherapy, physicians
responded that they use a LOPP very often (eight
responders, 54%), often (two responders, 13%), and
sometimes (five responders, 33%). Most physicians
strongly agreed (10 responders, 67%) that having
an LOPP modify chemotherapy orders is more efficient,
and the other physicians agreed (three responders,
20%) or were neutral (two, 13%). Apart from
making chemotherapy modifications more efficient,
physicians noted that they strongly agree (10 respon-
ders, 67%), agree (3 responders, 20%), and are neutral
(2 responders, 13%) towards the statement that having
an LOPP makes chemotherapy modifications faster.
When physicians were asked if the LOPP process
is beneficial, the responses were strongly agree
Table 2. LOPP survey questions.
Question Response type
How often do you interact with an LOPP? Physician
How often do you utilize LOPPs to make modifications to chemotherapy? Physician
Having an LOPP makes chemotherapy modifications a more efficient process. Physician
Having an LOPP makes chemotherapy modifications faster. Physician
I think the LOPP process is beneficial. Physician
I received adequate training for the LOPP responsibilities. LOPP (PA/NP/pharmacist)
I utilize my LOPP privileges. LOPP (PA/NP/pharmacist)
I think the LOPP process is beneficial. LOPP (PA/NP/pharmacist)
LOPPs streamline the chemotherapy modification process. LOPP (PA/NP/pharmacist)
Physicians think my LOPP responsibilities are valuable and helpful. LOPP (PA/NP/pharmacist)
LOPP: limited oncology practice provider; PA: physician assistants; NP: nurse practitioners.
Table 1. Continued
Knowledge Goal 4.2: Chemotherapy toxicities
Outline non-pharmacological management of extravasation
Describe pharmacological antidotes used in extravasation of chemo-
therapy agents (e.g. dexrazoxane, dimethyl sulfoxide, hyaluronidase
and sodium thiosulfate)
Describe the management of hypersensitivity reaction to a chemother-
apy agent
Identify scenarios when the management of hypersensitivity reaction to
chemotherapy should include slowing down the rate of infusion
Recall the standard operating procedures for tumor lysis syndrome
Explain and draw ‘‘chemo man,’’ ‘‘FABio’’ and ‘‘TYROne KINASE’’
Practical application of examining chemotherapy
orders (3 h)
Readings:
(1) Nursing policy: Extravasation/infiltration of caus-
tic agents prevention and treatment
(2) Management and preparedness for infusion and
hypersensitivity reactions
(3) Hypersensitivity reaction standing orderset
(4) Procedure on tumor lysis syndrome
LOPP: limited oncology practice provider; PA: physician assistants; NP: nurse practitioners.
(11 responders, 74%), agree (3 responders, 20%), and
neutral (1 responder, 7%).
The LOPPs provided similar perceptions about the
program. The majority of LOPPs strongly agreed or
agreed (8 responders, 47%, 8 responders 47%) that
the training they received was adequate, while only
one responder strongly disagreed (1 responder, 6%).
The majority of LOPPs indicated that they use their
LOPP privileges very often (9 responders, 53%) or
often (5 responders, 29%), while few were neutral (3
responders, 18%). Similar to the physicians, the major-
ity of LOPPs strongly agreed (11 responders, 65%) or
agreed (5 responders, 29%) the privileges are beneficial.
One responder (6%) somewhat disagreed the LOPP
process is beneficial. When asked about the perceptions
that LOPPs streamline the chemotherapy process,
LOPPs noted that they strongly agreed (10 responders,
59%) or agreed (4 responders 23%) with the statement,
and few were neutral (3 responders, 18%). Overall, the
majority of LOPPs strongly agreed (9 responders, 52%)
or agreed (6 responders, 36%) that their LOPP respon-
sibilities are valuable. Some LOPPs were neutral
(1 responder, 6%) or disagreed with the statement
(1 responder 6%).
Discussion
Oncology practices continue to adapt and evolve to
accommodate the growing population and needs of
patients with cancer and the systemic changes in health-
care. The inclusion of APPs in oncology care models, as
promoted by ASCO, provides the opportunity to dir-
ectly address increased patient care demands. APPs can
help streamline the requirements for patient care so that
oncology physicians are able to focus more of their time
and resources on patients.2 Better integration of APPs
could also improve patient outcomes and result in posi-
tive professional experiences for oncology care
providers.19
In order to best utilize APPs within oncology care, it
is essential to ensure that APPs are appropriately qua-
lified and trained to care for patients with cancer.19 The
American Society of Health-System Pharmacists rec-
ommends that all practice settings establish policies
and procedures to ensure that healthcare providers
that prescribe and manage chemotherapy are compe-
tent to perform these functions.13 Similarly, ASCO pro-
motes institutional privileging and credentialing as a
best practice recommendation, for clinicians to have
access to the order entry components for chemotherapy
within the EMR. This promotes an environment of
shared responsibility among providers and APPs and
also ensures that only qualified and approved providers
are able to order and manage chemotherapy.20
The number of cancer survivors and patients is
anticipated to continue to grow. APPs in oncology,
including NPs, PAs, and pharmacists have the educa-
tion and skills necessary to assist in filling the antici-
pated workforce shortage.21 The creation of LOPP
privileging has proved an effective way to integrate
APPs into oncology practice while reducing some phys-
ician demands. As demonstrated by the survey results,
LOPPs and physicians alike have benefitted.
Additionally, the inclusion of the privileging process
created a more streamlined process for chemotherapy
modifications and contributed to an overall better
patient experience by decreasing wait times and delays.
Chemotherapy prescribing and order management
are not immune to errors.22 Given the complex nature
of cancer care, a focused effort to train and educate
anyone with chemotherapy EMR editing privileges
must be implemented to ensure the safety and quality
of cancer care provided.21 To ensure the safety of our
patients, a requirement of an 80% pass rate for each
step of the LOPP privileging process is required.
Concerted efforts to fill educational gaps, by other insti-
tutions considering similar workflow implementations,
are recommended for all interdisciplinary oncology
team members with EMR chemotherapy privileges.
The results from this study support the use of APPs
within an academic medical center’s oncology practice
model. Limitations of this study included the grouping
together of NPs, PAs, and pharmacists within the
LOPP survey. Differentiation of specialties may have
assisted in identifying any current barriers to full opti-
mization of the LOPP designation. As distributed, any
potential differences of opinion between NP, PA, and
pharmacists are unable to be identified. Further inves-
tigation is needed to quantify the impact on patient
time savings, physician time savings, and the overall
operational efficiency.
Conclusion
Privileging of APPs to manage existing chemotherapy
orders can contribute to improved efficiency and
patient care. Creation of the LOPP designation at our
institution was the result of interdisciplinary collabor-
ation that has assisted in streamlining the care
Table 3. Survey responders.
Response rates Amount (n, %)
Physician 15 (42)
LOPP – PA/NP 10 (28)
LOPP – pharmacist 10 (28)
Total responders 35 (100)
LOPP: limited oncology practice provider; PA: physician assistants; NP:
nurse practitioners.
workflow process so that providers can focus more of
their time and efforts on direct patient care and so that
nursing staff could more efficiently deliver patient care.
The training required as part of the privileging process
ensures that oncology care is offered in a safe, timely,
and efficient manner.
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